TY - JOUR
T1 - Nephron sparing surgery (NSS) for unilateral wilms tumor (UWT)
T2 - The SIOP 2001 experience
AU - Wilde, Jim C.H.
AU - Aronson, Daniel C.
AU - Sznajder, Beata
AU - Van Tinteren, Harm
AU - Powis, Mark
AU - Okoye, Bruce
AU - Cecchetto, Giovanni
AU - Audry, Georges
AU - Fuchs, Jörg
AU - Schweinitz, Dietrich Von
AU - Heij, Hugo
AU - Graf, Norbert
AU - Bergeron, Christophe
AU - Pritchard-Jones, Kathy
AU - Van Den Heuvel-Eibrink, Marry
AU - Carli, Modesto
AU - Oldenburger, Foppe
AU - Sandstedt, Bengt
AU - De Kraker, Jan
AU - Godzinski, Jan
N1 - Publisher Copyright:
© 2014 Wiley Periodicals, Inc.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Background: Total nephrectomy (TN) remains the standard treatment of unilateral Wilms tumors (uWT). The SIOP WT-2001 protocol allowed Nephron Sparing Surgery (NSS) for polar or peripherally non-infiltrating tumors. Aim: Inventory of the current SIOP NSS-experience. Procedures: 2,800 patients with a unilateral, localized or metastatic and an unequivocal surgical technique recorded were included. All had neo-adjuvant chemotherapy and delayed surgery. In 91 (3%) NSS was performed and in 2709 TN. Data was retrieved from the SIOP WT 2001 database. Results: NSS group contained 65% stage I tumours and the TN group 48%. Tumor volume (at diagnosis and surgery) was significantly smaller in the NSS group. Within stage III, after NSS, 7/12 (58%) had positive margins (M+), 5 with tumor negative lymph nodes (LN-). After TN, 355/712 (55%) had M+, 182 were LN- Treatment of M+ in the NSS group resulted in two conversions to TN (one combined with radiotherapy), three patients had radiotherapy only and in two patients local therapy, if given, was not recorded. After NSS, four recurrences occurred. For localized disease the 5-year overall (OS) and event free survival (EFS) in NSS group was 100 and 94.8 (95% CI:89.9-99.9), respectively, while OS and EFS in the TN group were 94.4 (95% CI: 93.2-95.5, log-rank test P=0.06) and 86.5 (95% CI:85.0-88.1, log-rank test P=0.06), respectively. Conclusions: NSS was only performed in 3% of patients with uWT. Despite excellent survival with few relapses, the gain of nephrons needs to be weighed against the risk to induce stage III with intensified therapy.
AB - Background: Total nephrectomy (TN) remains the standard treatment of unilateral Wilms tumors (uWT). The SIOP WT-2001 protocol allowed Nephron Sparing Surgery (NSS) for polar or peripherally non-infiltrating tumors. Aim: Inventory of the current SIOP NSS-experience. Procedures: 2,800 patients with a unilateral, localized or metastatic and an unequivocal surgical technique recorded were included. All had neo-adjuvant chemotherapy and delayed surgery. In 91 (3%) NSS was performed and in 2709 TN. Data was retrieved from the SIOP WT 2001 database. Results: NSS group contained 65% stage I tumours and the TN group 48%. Tumor volume (at diagnosis and surgery) was significantly smaller in the NSS group. Within stage III, after NSS, 7/12 (58%) had positive margins (M+), 5 with tumor negative lymph nodes (LN-). After TN, 355/712 (55%) had M+, 182 were LN- Treatment of M+ in the NSS group resulted in two conversions to TN (one combined with radiotherapy), three patients had radiotherapy only and in two patients local therapy, if given, was not recorded. After NSS, four recurrences occurred. For localized disease the 5-year overall (OS) and event free survival (EFS) in NSS group was 100 and 94.8 (95% CI:89.9-99.9), respectively, while OS and EFS in the TN group were 94.4 (95% CI: 93.2-95.5, log-rank test P=0.06) and 86.5 (95% CI:85.0-88.1, log-rank test P=0.06), respectively. Conclusions: NSS was only performed in 3% of patients with uWT. Despite excellent survival with few relapses, the gain of nephrons needs to be weighed against the risk to induce stage III with intensified therapy.
KW - Nephroblastoma
KW - Nephron sparing surgery
KW - Partial nephrectomy
KW - Unilateral nephroblastoma
KW - Unilateral Wilms tumor
KW - Wilms tumor
UR - http://www.scopus.com/inward/record.url?scp=84911479347&partnerID=8YFLogxK
U2 - 10.1002/pbc.25185
DO - 10.1002/pbc.25185
M3 - Article
C2 - 25156758
AN - SCOPUS:84911479347
SN - 1545-5009
VL - 61
SP - 2175
EP - 2179
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 12
ER -